Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunovant (IMVT) Cash & Equivalents (2018 - 2026)

Immunovant filings provide 8 years of Cash & Equivalents readings, the most recent being $994.5 million for Q4 2025.

  • Quarterly Cash & Equivalents rose 165.42% to $994.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $994.5 million through Dec 2025, up 165.42% year-over-year, with the annual reading at $714.0 million for FY2025, 12.37% up from the prior year.
  • Cash & Equivalents hit $994.5 million in Q4 2025 for Immunovant, up from $521.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $994.5 million in Q4 2025 and bottomed at $269.9 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $513.9 million, with a median of $493.8 million recorded in 2022.
  • The largest annual shift saw Cash & Equivalents plummeted 45.77% in 2024 before it skyrocketed 165.42% in 2025.
  • Immunovant's Cash & Equivalents stood at $527.0 million in 2021, then dropped by 17.91% to $432.6 million in 2022, then surged by 59.72% to $690.9 million in 2023, then plummeted by 45.77% to $374.7 million in 2024, then soared by 165.42% to $994.5 million in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Cash & Equivalents are $994.5 million (Q4 2025), $521.9 million (Q3 2025), and $598.9 million (Q2 2025).